- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Donepezil does not improve chemotherapy-related cognitive impairment: Study
Many breast cancer survivors report cancer-related cognitive impairment following chemotherapy, although prevalence rates and severity vary.
To test whether a dementia drug could improve cognition in breast cancer survivors, researchers at Wake Forest University School of Medicine conducted a Phase III randomized, placebo-controlled trial to test donepezil, a cognitive-enhancing medicine used in the treatment of Alzheimer’s disease.
The research team found that donepezil did not improve memory or other cognitive functions in survivors with cancer-related cognitive impairment.
The findings appear online in the Journal of Clinical Oncology.
The researchers enrolled 276 breast cancer survivors from community oncology practices affiliated with the National Cancer Institute Community Oncology Research Program (NCORP), a national network that brings cancer clinical trials and care delivery studies to communities. The Wake Forest NCORP Research Base at Atrium Health Wake Forest Baptist’s National Cancer Institute-designated Comprehensive Cancer Center is one of seven funded NCORP Research Program bases in the country.
Study participants had received at least four cycles of adjuvant chemotherapy and reported cognitive impairment and memory problems for one to five years after chemotherapy had completed. Participants were enrolled on the NCORP study between July 2017 and July 2021.
“The participants were assigned to either receive 5-10 mg of donepezil, taken once a day for 24 weeks, or placebo,” said Stephen R. Rapp, Ph.D., professor of psychiatry and behavioral medicine at Wake Forest University School of Medicine and lead author of the paper.
Cognitive assessments were conducted before treatment, at 12 weeks and at end of treatment.
“We found that the participants did not perform differently at the end of treatment on tests of memory, other cognitive functions, or subjective functioning than those randomly assigned to placebo,” Rapp said.
While donepezil cannot be recommended as a treatment to improve cancer-related cognitive impairment in breast cancer survivors after completing chemotherapy, the researchers say further trials are needed.
“Additional research with different timing of administration, different medications or medication combinations, or non-pharmacological interventions are warranted,” said Glenn Lesser, M.D., deputy director of the Atrium Health Wake Forest Baptist Comprehensive Cancer Center, senior author of the manuscript and principal investigator of the Wake Forest NCORP Research Base.
Reference:
Stephen R. Rapp, Emily V. Dressler, W. Mark Brown, James L. Wade III, Nguyet Le-Lindqwister, David King, Kendrith M. Rowland, Kathryn E. Weaver, Heidi D. Klepin, Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116), Journal of Clinical Oncology, https://doi.org/10.1200/JCO.23.01100.
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751